

BIOCON GROUP

FACT SHEET

Mar/12

**FY 2012 vs. FY 2011
Q4 FY 2012 vs. Q4 FY 2011**

BIOCON LIMITED (CONSOLIDATED) UNAUDITED		
BALANCE SHEET		<i>(Rs. Millions)</i>
	March 31, 2012	March 31, 2011
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	1,000	1,000
(b) Reserves and surplus	21,725	19,328
	22,725	20,328
Minority interest	38	377
Non-current liabilities		
(a) Long-term borrowings	699	658
(b) Deferred Tax Liability (net)	-	497
(c) Other long-term liabilities	5,832	3,390
	6,531	4,544
Current liabilities		
(a) Short-term borrowings	1,873	2,475
(b) Trade payables	3,478	2,965
(c) Other current liabilities	2,689	3,755
(d) Short-term provisions	2,115	1,410
	10,154	10,605
TOTAL	39,448	35,854
ASSETS		
Non-current assets		
(a) Fixed Assets	16,594	15,602
(b) Non-current investments	643	609
(c) Deferred Tax Asset (net)	78	-
(d) Other non-current assets	2,455	1,574
	19,770	17,784
Current assets		
(a) Current Investments	4,921	3,995
(b) Inventories	3,783	4,136
(c) Trade Receivables	4,815	4,852
(d) Cash and cash equivalents	5,232	4,414
(e) Short term loans and advances	95	46
(f) Other current assets	830	627
	19,678	18,070
TOTAL	39,448	35,854

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT**

(Rs. Millions)

Particulars	Q4 FY 12	Q3 FY 12	Variance	Q4 FY 11	Variance
INCOME					
Biopharmaceuticals	4,272	3,360	27%	3,337	28%
Branded formulations - India	650	720	-10%	485	34%
Total Biopharmaceuticals	4,922	4,080	21%	3,822	29%
Contract research	1,180	1,120	5%	888	33%
Total Sales	6,102	5,200	17%	4,710	30%
Other income	13	157	-92%	169	-92%
Total Revenue	6,115	5,357	14%	4,879	25%
EXPENDITURE					
Material & Power Costs	2,771	2,332	19%	2,315	20%
Staff costs	761	732	4%	584	30%
Research & Development	726	330	120%	223	226%
Other Expenses	298	543	-45%	280	6%
Manufacturing, staff & other expenses	4,556	3,937	16%	3,402	34%
PBDIT /EBITDA	1,559	1,420	10%	1,477	6%
Interest and finance charges	30	24	25%	50	-40%
Depreciation & Amortisation	431	434	-1%	382	13%
PBT	1,098	962	14%	1,045	5%
Taxes	120	113	6%	103	17%
NET PROFIT (PAT) WITHOUT AXICORP	978	849	15%	942	4%
Profit from discontinued (AxiCorp) Operations, net	-	-		66	
NET PROFIT FOR THE PERIOD	978	849	15%	1,008	-3%
EPS Rs.	4.9	4.2		5.0	
<i>Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers</i>					
Biopharmaceuticals Income includes:					
Licensing development fees	463	292		580	
Licensing Income	-	-		188	

BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT (Rs. Millions)

Particulars	12M FY 12	12M FY 11	Variance
INCOME			
Biopharmaceuticals	14,170	13,023	9%
Branded formulations - India	2,594	1,863	39%
Total Biopharmaceuticals	16,764	14,886	13%
Contract research	4,101	3,177	29%
Total Sales	20,865	18,063	16%
Other income	618	516	20%
Total Revenue	21,483	18,579	16%
EXPENDITURE			
Material & Power Costs	9,486	8,081	17%
Staff costs	2,866	2,188	31%
Research & Development	1,566	1,183	32%
Other Expenses	1,773	1,394	27%
Manufacturing, staff & other expenses	15,691	12,846	22%
PBDIT /EBITDA	5,792	5,733	1%
Interest and finance charges	123	230	-46%
Depreciation & Amortisation	1,744	1,516	15%
PBT	3,925	3,987	-2%
Taxes	541	588	-8%
NET PROFIT (PAT) WITHOUT AXICORP	3,384	3,399	0%
Profit from discontinued (AxiCorp) Operations, net	-	276	
NET PROFIT FOR THE PERIOD	3,384	3,675	-8%
EPS Rs.	16.9	18.4	
<i>Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers</i>			
Biopharmaceuticals Income includes:			
Licensing development fees	1,253	610	
Licensing Income	13	915	